DA
MRNS

Denali Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Denali Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,600
Closed -$123K – 476
2024
Q1 		$123K Hold
13,600
– – 0.04% 264
2023
Q4 		$148K Sell
13,600
-13,000
-49% -$97.4K 0.05% 250
2023
Q3 		$214K Sell
26,600
-26,000
-49% -$216K 0.08% 219
2023
Q2 		$571K Buy
52,600
+43,000
+448% +$368K 0.2% 129
2023
Q1 		$66.2K Buy
+9,600
New +$60.2K 0.03% 200

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Denali Advisors's MRNS Position: Q2 2024 in Review

Denali Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 13,600 shares — an estimated $123K sold.

Denali Advisors first reported a position in MRNS in Q1 2023 and held it in 5 quarters. The position peaked at $571K in Q2 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Denali Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 13,600 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $123K.
  • Denali Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q1 2023 and held it in 5 quarters.
  • Denali Advisors's Marinus Pharmaceuticals, Inc position peaked at $571K in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.